Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00248248 · ClinicalTrials.gov registry record · Phase 2
DOXIL for Consolidation Therapy in Ovarian Cancer.
A Phase 2 study of Ovarian Neoplasm, sponsored by Southeastern Gynecologic Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT00248248: Completed Phase 2 study of Ovarian Neoplasm, sponsored by Southeastern Gynecologic Oncology.
NCT00248248 is a Phase 2 study of Ovarian Neoplasm that has completed, run by Southeastern Gynecologic Oncology. The registered enrollment target is 45 participants, below the 405-participant average among 7 other Ovarian Neoplasm trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00248248, a Phase 2 study of Ovarian Neoplasm, has completed, sponsored by Southeastern Gynecologic Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective for this study is to evaluate the development, frequency and severity of hand foot syndrome (HFS) in ovarian cancer subjects treated with Doxil®, as consolidation therapy, on an every two week schedule. The secondary objective for this study is to assess one-year progression free survival rate (PFS).
Conditions Studied
Interventions
- DRUG liposomal doxorubicin
Study Locations (1)
Georgia
- Southeastern Gynecologic Oncology - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2005-10 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
What the finished NCT00248248 record still lists
NCT00248248 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 405-participant average among 7 other Ovarian Neoplasm trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Ovarian Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which liposomal doxorubicin is the first listed.
NCT00248248 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT00248248 about?
NCT00248248 is a clinical study titled "DOXIL for Consolidation Therapy in Ovarian Cancer.". The primary objective for this study is to evaluate the development, frequency and severity of hand foot syndrome (HFS) in ovarian cancer subjects treated with Doxil®, as consolidation therapy, on an every two week schedule. The secondary objective for this study is to assess one-year progression f...
What is the current status of trial NCT00248248?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2005-10. Estimated completion is 2011-10.
What conditions does trial NCT00248248 study?
This clinical trial studies the following conditions: Ovarian Neoplasm.
What interventions are being tested in trial NCT00248248?
The interventions under investigation include: liposomal doxorubicin (DRUG).
Who is sponsoring clinical trial NCT00248248?
This trial is sponsored by Southeastern Gynecologic Oncology, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00248248 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Survivorship Care for Women Living With Ovarian Cancer: (POSTCARE-O)
RECRUITING · NA
-
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
EHealth Mindful Movement and Breathing in Improving Outcomes in Participants Undergoing Gynecologic Surgery
COMPLETED · NA
-
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2
COMPLETED · Phase 1
-
Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia